Celltrion (068270.KS) Stock Price

Celltrion Price

KOSDAQ·CLOSED
183,000.00KRW-3,700.00 (-2.00 %)
Market closed

Over the last 19 years Celltrion grew revenue by 27.4% annually, reaching 3.56 T KRW. Earnings per share have grown at 7.7% per year over the last 19 years. For Celltrion, the net margin of 11.9% is down versus 28.0% a few years ago. At today's price the dividend yield works out to roughly 0.39%. The payout ratio is around 33% of earnings. The dividend has grown at 15.9% per year over the past 18 years. The consensus 12-month price target for Celltrion is 255,000.00 KRW, about 39.3% above where the stock trades today. Of 28 analysts, 24 rate the stock a buy — an overall Buy consensus. The stock trades about 14% above its 52-week low.

Celltrion stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Celltrion over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Celltrion stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Celltrion's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Celltrion Stock Price History
DateCelltrion Price
8/3/2026183,000.00 KRW
7/31/2026186,700.00 KRW
7/30/2026189,800.00 KRW
7/29/2026180,000.00 KRW
7/28/2026177,400.00 KRW
7/27/2026180,000.00 KRW
7/24/2026177,600.00 KRW
7/23/2026172,200.00 KRW
7/22/2026170,100.00 KRW
7/21/2026171,600.00 KRW
7/20/2026173,600.00 KRW
7/16/2026175,800.00 KRW
7/15/2026177,400.00 KRW
7/14/2026175,600.00 KRW
7/13/2026178,700.00 KRW
7/10/2026177,900.00 KRW
7/9/2026171,700.00 KRW
7/8/2026176,800.00 KRW
7/7/2026178,200.00 KRW
7/6/2026175,900.00 KRW
7/3/2026183,700.00 KRW
7/2/2026179,500.00 KRW
7/1/2026174,400.00 KRW
6/30/2026176,100.00 KRW
6/29/2026176,900.00 KRW
6/26/2026161,900.00 KRW
6/25/2026178,500.00 KRW
6/24/2026172,800.00 KRW
6/23/2026160,500.00 KRW
6/22/2026168,500.00 KRW
6/19/2026170,000.00 KRW
6/18/2026173,300.00 KRW
6/17/2026176,800.00 KRW
6/16/2026174,800.00 KRW
6/15/2026175,600.00 KRW
6/12/2026176,600.00 KRW
6/11/2026163,300.00 KRW
6/10/2026166,600.00 KRW
6/9/2026170,000.00 KRW
6/8/2026160,900.00 KRW
6/5/2026170,900.00 KRW
6/4/2026177,300.00 KRW
6/2/2026188,700.00 KRW
6/1/2026192,100.00 KRW
5/29/2026192,550.00 KRW
5/28/2026188,600.00 KRW
5/27/2026195,250.00 KRW
5/26/2026196,200.00 KRW
5/22/2026198,200.00 KRW
5/21/2026189,100.00 KRW
5/20/2026178,500.00 KRW
5/19/2026182,500.00 KRW
5/18/2026183,200.00 KRW
5/15/2026191,900.00 KRW
5/14/2026193,200.00 KRW
5/13/2026190,500.00 KRW
5/12/2026193,300.00 KRW
5/11/2026191,300.00 KRW
5/8/2026198,400.00 KRW
5/7/2026202,500.00 KRW
5/6/2026194,700.00 KRW
5/4/2026197,800.00 KRW
4/30/2026200,500.00 KRW
4/29/2026204,000.00 KRW
4/28/2026207,000.00 KRW
4/27/2026204,000.00 KRW
4/24/2026209,000.00 KRW
4/23/2026206,000.00 KRW
4/22/2026204,000.00 KRW
4/21/2026203,000.00 KRW
4/20/2026205,500.00 KRW
4/17/2026207,500.00 KRW
4/16/2026209,000.00 KRW
4/15/2026202,000.00 KRW
4/14/2026199,100.00 KRW
4/13/2026195,200.00 KRW
4/10/2026199,700.00 KRW
4/9/2026201,500.00 KRW
4/8/2026202,000.00 KRW
4/7/2026193,700.00 KRW
4/6/2026195,800.00 KRW
4/3/2026195,300.00 KRW
3/27/2026206,000.00 KRW
3/26/2026203,000.00 KRW
3/25/2026203,500.00 KRW
3/24/2026199,600.00 KRW
3/23/2026188,300.00 KRW
3/20/2026202,000.00 KRW
3/19/2026202,000.00 KRW
3/18/2026209,500.00 KRW
3/17/2026206,000.00 KRW
3/16/2026200,000.00 KRW
3/13/2026205,500.00 KRW
3/12/2026206,000.00 KRW
3/11/2026209,000.00 KRW
3/10/2026206,000.00 KRW
3/9/2026204,000.00 KRW
3/6/2026212,500.00 KRW
3/5/2026211,500.00 KRW
3/4/2026197,400.00 KRW
3/3/2026225,000.00 KRW
2/27/2026238,500.00 KRW
2/26/2026242,000.00 KRW
2/25/2026244,500.00 KRW
2/24/2026248,500.00 KRW
2/23/2026243,000.00 KRW
2/20/2026242,000.00 KRW
2/19/2026244,500.00 KRW
2/13/2026238,000.00 KRW
2/12/2026238,500.00 KRW
2/11/2026239,500.00 KRW
2/10/2026227,500.00 KRW
2/9/2026230,000.00 KRW
2/6/2026220,000.00 KRW
2/5/2026217,500.00 KRW
2/4/2026214,500.00 KRW
2/3/2026207,500.00 KRW
2/2/2026203,000.00 KRW
1/30/2026210,000.00 KRW
1/29/2026214,500.00 KRW
1/28/2026218,500.00 KRW
1/27/2026211,500.00 KRW
1/26/2026215,000.00 KRW
1/23/2026212,000.00 KRW
1/22/2026208,000.00 KRW
1/21/2026204,000.00 KRW
1/20/2026207,000.00 KRW
1/19/2026206,500.00 KRW
1/16/2026209,000.00 KRW
1/15/2026210,500.00 KRW
1/14/2026211,500.00 KRW
1/13/2026220,000.00 KRW
1/12/2026214,000.00 KRW
1/9/2026217,000.00 KRW
1/8/2026213,000.00 KRW
1/7/2026211,000.00 KRW
1/6/2026213,000.00 KRW
1/5/2026209,500.00 KRW
1/2/2026202,500.00 KRW
12/30/2025181,000.00 KRW
12/29/2025181,300.00 KRW
12/26/2025180,000.00 KRW
12/24/2025182,000.00 KRW
12/23/2025182,800.00 KRW
12/22/2025184,600.00 KRW
12/19/2025184,500.00 KRW
12/18/2025182,100.00 KRW
12/17/2025185,000.00 KRW
12/16/2025185,600.00 KRW
12/15/2025187,800.00 KRW
12/12/2025186,800.00 KRW
12/11/2025186,700.00 KRW
12/10/2025185,700.00 KRW
12/9/2025187,300.00 KRW
12/8/2025187,100.00 KRW
12/5/2025183,300.00 KRW
12/4/2025182,600.00 KRW
12/3/2025183,300.00 KRW
12/2/2025184,200.00 KRW
12/1/2025185,800.00 KRW
11/28/2025185,600.00 KRW
11/27/2025185,200.00 KRW
11/26/2025187,400.00 KRW
11/25/2025182,500.00 KRW
11/24/2025182,100.00 KRW
11/21/2025187,400.00 KRW
11/20/2025186,800.00 KRW
11/19/2025185,100.00 KRW
11/18/2025183,800.00 KRW
11/17/2025189,900.00 KRW
11/14/2025196,100.00 KRW
11/13/2025195,100.00 KRW
11/12/2025182,900.00 KRW
11/11/2025172,800.00 KRW
11/10/2025173,600.00 KRW
11/7/2025172,900.00 KRW
11/6/2025174,700.00 KRW
11/5/2025174,900.00 KRW
11/4/2025176,300.00 KRW
11/3/2025174,600.00 KRW
10/31/2025175,600.00 KRW
10/30/2025175,100.00 KRW
10/29/2025176,600.00 KRW
10/28/2025179,300.00 KRW
10/27/2025178,400.00 KRW
10/24/2025172,900.00 KRW
10/23/2025172,600.00 KRW
10/22/2025178,300.00 KRW
10/21/2025178,700.00 KRW
10/20/2025177,100.00 KRW
10/17/2025175,000.00 KRW
10/16/2025176,000.00 KRW
10/15/2025171,200.00 KRW
10/14/2025169,700.00 KRW
10/13/2025170,900.00 KRW
10/10/2025173,600.00 KRW
10/2/2025175,400.00 KRW
10/1/2025175,100.00 KRW
9/30/2025173,400.00 KRW
9/29/2025178,600.00 KRW
9/26/2025178,000.00 KRW
9/25/2025177,900.00 KRW
9/24/2025176,900.00 KRW
9/23/2025184,200.00 KRW
9/22/2025169,100.00 KRW
9/19/2025170,800.00 KRW
9/18/2025168,500.00 KRW
9/17/2025168,400.00 KRW
9/16/2025168,700.00 KRW
9/15/2025170,000.00 KRW
9/12/2025171,700.00 KRW
9/11/2025172,000.00 KRW
9/10/2025169,700.00 KRW
9/9/2025169,500.00 KRW
9/8/2025170,000.00 KRW
9/5/2025169,000.00 KRW
9/4/2025170,200.00 KRW
9/3/2025171,500.00 KRW
9/2/2025171,200.00 KRW
9/1/2025169,800.00 KRW
8/29/2025167,600.00 KRW
8/28/2025172,400.00 KRW
8/27/2025170,800.00 KRW
8/26/2025172,900.00 KRW
8/25/2025174,300.00 KRW
8/22/2025173,800.00 KRW
8/21/2025171,300.00 KRW
8/20/2025172,000.00 KRW
8/19/2025172,900.00 KRW
8/18/2025172,900.00 KRW
8/14/2025175,000.00 KRW
8/13/2025176,000.00 KRW
8/12/2025172,400.00 KRW
8/11/2025173,000.00 KRW
8/8/2025174,100.00 KRW
8/7/2025172,500.00 KRW
8/6/2025178,500.00 KRW
Access this data via the Eulerpool API
Get Free API Key

Celltrion Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
2.28 T KRW
647.20 B KRW
537.84 B KRW
Jan 1, 2023
2.18 T KRW
651.48 B KRW
535.65 B KRW
Jan 1, 2024
3.56 T KRW
492.02 B KRW
422.69 B KRW
Jan 1, 2025 (e)
4.14 T KRW
1.20 T KRW
801.52 B KRW
Jan 1, 2026 (e)
5.36 T KRW
1.55 T KRW
1.37 T KRW
Jan 1, 2027 (e)
6.14 T KRW
1.78 T KRW
1.54 T KRW
Jan 1, 2028 (e)
6.92 T KRW
2.01 T KRW
1.83 T KRW
Jan 1, 2029 (e)
6.83 T KRW
1.98 T KRW
2.29 T KRW

Celltrion Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 8:48 PM
 
REVENUET KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMET KRW
EBITT KRW
EBIT MARGIN%
NET INCOMET KRW
NET INCOME GROWTH%
DIV.KRW
DIV. GROWTH%
SHARESM
201420152016201720182019202020212022202320242025e2026e2027e2028e2029e
0.470.600.670.950.981.131.851.892.282.183.564.145.366.146.926.83
108.2428.1011.1341.533.4814.9163.862.3920.63-4.7163.4516.4929.3614.5412.75-1.38
72.4261.7758.2673.1956.1056.1455.5857.4445.2248.3347.2747.2747.2747.2747.2747.27
0.340.370.390.690.550.631.031.091.031.051.681.962.532.903.273.23
0.200.240.220.510.320.380.720.740.650.650.491.201.551.782.011.98
42.7740.1532.9953.5132.9033.8138.8639.3028.3429.9313.8328.9728.9728.9728.9728.97
0.110.150.160.380.250.300.520.580.540.540.420.801.371.541.832.29
9.9829.968.56140.61-35.7422.4972.0011.92-7.18-0.41-21.0989.6271.1711.9118.9025.58
–––––––735.29360.58500.00714.29714.29857.141,028.57––
––––––––-50.9638.6742.86–20.0020.00––
148.64149.01153.53161.71159.18153.94158.79152.82151.04155.86214.65214.65214.65214.65214.65214.65
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Celltrion generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Celltrion retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Celltrion's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Celltrion has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Celltrion's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Celltrion stock margins

The Celltrion margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Celltrion. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Celltrion.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
55.58 %
38.86 %
28.00 %
Jan 1, 2021
57.44 %
39.30 %
30.60 %
Jan 1, 2022
45.22 %
28.34 %
23.55 %
Jan 1, 2023
48.33 %
29.93 %
24.61 %
Jan 1, 2024
47.27 %
13.83 %
11.88 %
Jan 1, 2025 (e)
47.27 %
28.97 %
19.34 %
Jan 1, 2026 (e)
47.27 %
28.97 %
25.59 %
Jan 1, 2027 (e)
47.27 %
28.97 %
25.01 %

Celltrion Stock Revenue, EBIT, Earnings per Share

The Celltrion earnings per share therefore indicates how much revenue Celltrion has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
11,196.91 KRW
4,351.19 KRW
3,135.18 KRW
Jan 1, 2021
11,913.45 KRW
4,682.43 KRW
3,646.04 KRW
Jan 1, 2022
14,539.61 KRW
4,120.03 KRW
3,423.83 KRW
Jan 1, 2023
13,427.32 KRW
4,019.26 KRW
3,304.64 KRW
Jan 1, 2024
15,935.29 KRW
2,204.03 KRW
1,893.49 KRW
Jan 1, 2025 (e)
18,563.36 KRW
5,376.97 KRW
3,590.49 KRW
Jan 1, 2026 (e)
24,013.94 KRW
6,955.76 KRW
6,145.89 KRW
Jan 1, 2027 (e)
27,505.11 KRW
7,967.00 KRW
6,877.83 KRW

Celltrion business model & stock analysis

Celltrion Inc is a South Korean company that was founded in 2002 and specializes in the development and manufacturing of biopharmaceutical products. The company is headquartered in Incheon, South Korea and employs over 2,000 people worldwide.

Celltrion SWOT Analysis

Strengths

Celltrion Inc has a strong portfolio of innovative, high-quality biopharmaceutical products.

The company has a robust research and development division, investing in cutting-edge technologies to fuel future growth.

Celltrion Inc has established strong partnerships with global pharmaceutical companies, enabling it to expand its market reach.

Weaknesses

Celltrion Inc faces the challenge of increasing competition, with other companies also focusing on the biopharmaceutical sector.

The company heavily relies on a limited number of key products, making it vulnerable to potential market fluctuations.

Celltrion Inc's manufacturing processes are complex, requiring consistent quality control measures to maintain product efficacy.

Opportunities

The growing global demand for biologics provides Celltrion Inc with opportunities to expand its market presence.

The company can leverage its expertise in biosimilar development to enter emerging markets and capture untapped potential.

Celltrion Inc can explore strategic collaborations and licensing deals to further enhance its product pipeline and market opportunities.

Threats

Regulatory challenges and changing governmental policies regarding biopharmaceuticals can pose threats to Celltrion Inc's operations.

Intense competition from both established pharmaceutical companies and emerging biotech firms may impact the company's market share.

Economic fluctuations and global macroeconomic factors can impact demand for Celltrion Inc's products.

Celltrion Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Celltrion historical P/E ratio, EBIT multiple, and P/S ratio

Celltrion annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Celltrion shares outstanding

The number of shares of Celltrion was 223.23 M in 2025. This indicates how many shares Celltrion is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
165.15 M Stocks
Jan 1, 2021
158.93 M Stocks
Jan 1, 2022
157.09 M Stocks
Jan 1, 2023
162.09 M Stocks
Jan 1, 2024
223.23 M Stocks
Jan 1, 2025 (e)
223.23 M Stocks
Jan 1, 2026 (e)
223.23 M Stocks
Jan 1, 2027 (e)
223.23 M Stocks

Celltrion stock splits

In Celltrion's history, there have been no stock splits.

Celltrion Dividend History

12 years of dividend payments · 3 consecutive increases

YearAnnual DividendYoY ChangePayments
2025750.00KRW↑ 5.0%1×
Dec 29, 2025750.00KRW↑ 5.0%1/1
2024714.29KRW↑ 42.9%1×
2023500.00KRW↑ 38.7%1×
2022360.58KRW↓ 51.0%1×
2021735.29KRW↑ 4,417.8%1×
201316.28KRW↑ 24.8%—
201213.04KRW↓ 87.0%1×
2011100.00KRW↑ 33.3%1×
201075.00KRW↑ 105.1%1×
200836.57KRW↓ 26.9%—

Celltrion dividend history and estimates

In 2025, Celltrion paid a dividend amounting to 714.29 KRW. Dividend means that Celltrion distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2013
16.28 KRW
0.00 KRW
Jan 1, 2021
735.29 KRW
0.00 KRW
Jan 1, 2022
360.58 KRW
0.00 KRW
Jan 1, 2023
500.00 KRW
0.00 KRW
Jan 1, 2024
714.29 KRW
0.00 KRW
Jan 1, 2025
714.29 KRW
0.00 KRW
Jan 1, 2026 (e)
0.00 KRW
857.14 KRW
Jan 1, 2027 (e)
0.00 KRW
1,028.57 KRW

Celltrion dividend payout ratio

In 2025, Celltrion had a payout ratio of 19.13%. The payout ratio indicates the percentage of the company's profits that Celltrion distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
18.36 %
Jan 1, 2021
16.59 %
Jan 1, 2022
9.18 %
Jan 1, 2023
12.69 %
Jan 1, 2024
33.22 %
Jan 1, 2025 (e)
19.13 %
Jan 1, 2026 (e)
13.41 %
Jan 1, 2027 (e)
14.38 %

Current Celltrion forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
4.17 %
Buy
85.71 % (24)
Hold
10.71 % (3)
Sell
3.57 % (1)
12M Price Target
255,000.00
Last Price
191,000.00
Currency
KRW
12M Return Potential
33.51 %
LTM Return
0 %

Celltrion Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/6/2024868.98KRW-689.47 BKRW-2024 Q1
3/1/2024954.46KRW-634.59 BKRW-2023 Q4
8/3/20231,166.37KRW-682.72 BKRW-2023 Q2
5/10/20231,001.72KRW-639.18 BKRW-2023 Q1
2/14/2023979.36KRW-622.56 BKRW-2022 Q4
11/8/20221,018.94KRW-567.83 BKRW-2022 Q3
8/5/2022965.92KRW-529.34 BKRW-2022 Q2
5/16/2022966.12KRW-555.91 BKRW-2022 Q1
2/16/2022924.05KRW-602.14 BKRW-2021 Q4
11/10/20211,353.64KRW-574.12 BKRW-2021 Q3

EESG©

Eulerpool ESG Scorecard© for the Celltrion stock

77/100
73
Environment
99
Social
57
Governance
E

Environment

20
Scope 1 - Direct Emissions22,457
Scope 2 - Indirect emissions from purchased energy42,260
Scope 3 - Indirect emissions within the value chain28,798
Total CO₂ emissions64,717
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees42
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Celltrion shareholder structure

% Name
26.57742%
Celltrion Holdings Company Ltd.
Celltrion Holdings Company Ltd.
2.18910%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.02685%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
1.06679%
Samsung Asset Management Co., Ltd.
Samsung Asset Management Co., Ltd.
0.75176%
Mirae Asset Global Investments Co., Ltd.
Mirae Asset Global Investments Co., Ltd.
0.67959%
BlackRock Advisors (UK) Limited
BlackRock Advisors (UK) Limited
...

Celltrion Beneficial Ownership Filings (SEC 13D/G)

Free Float
66.4%
Float Shares
-
Shares Outstanding
-

Celltrion Executives and Management Board

43 members · avg. age 54 · 19 % women

WG

Mr. Wu Seong Gi (62)

Co-Chief Executive Officer, Vice Chairman · since 2008

1.78 B KRW

Management

JS

Mr. Jin Seok Seo (39)

Co-Chief Executive Officer, Director

1.75 B KRW
SS

Ms. Su Eun Song (52)

Assistant Managing Director

1.50 B KRW
GG

Mr. Gi Seong Gwon (55)

Vice President · since 2023

704.00 M KRW
SL

Mr. Sang Jun Lee (57)

Senior Vice President · since 2018

579.00 M KRW
MS

Mr. Min Cheol Shin (52)

Vice President · since 2021

556.00 M KRW
JY

Mr. Jeong Won Yoon (57)

President

–

Board of Directors

JS

Mr. Jeong Jin Seo (66)

Chairman · since 2008

1.23 B KRW
JS

Mr. Jeong Su Seo (64)

Vice Chairman · since 2024

–
JS

Mr. Jun Seok Seo (37)

Senior Vice Chairman

–
JC

Mr. Jong Mun Choi (65)

Non-Executive Independent Director

–
WC

Ms. Won Gyeong Choi (50)

Non-Executive Independent Director

–
YG

Ms. Yeong Hye Goh (69)

Non-Executive Independent Director

–

Frequently asked questions about Celltrion

Celltrion Inc's business model focuses on the development, manufacturing, and sales of biopharmaceutical products. As a global biotechnology company, Celltrion specializes in the production of biosimilars, which are highly similar versions of existing biological medicines. By utilizing advanced technology and innovative research, Celltrion aims to provide affordable and accessible treatments to patients worldwide. The company's key strategies involve extensive research and development efforts to expand its product portfolio, strategic collaborations with international partners, and a commitment to enhancing healthcare accessibility. Through its business model, Celltrion Inc strives to contribute to the advancement of the pharmaceutical industry and positively impact patient lives.

Celltrion Inc is primarily active in the biopharmaceutical industry.

The main competitors of Celltrion Inc in the market include leading biopharmaceutical companies such as Samsung Bioepis, Pfizer Inc., Amgen Inc., and Roche Holding AG. These companies are actively engaged in the development and commercialization of innovative biologic medicines, which may compete with Celltrion's biosimilar products in various therapeutic areas. Celltrion, however, has established a strong market presence and competitive advantage through its expertise in biosimilars manufacturing, research and development capabilities, and strategic partnerships.

Celltrion Inc, a renowned biopharmaceutical company based in South Korea, was founded in 2002. With a strong focus on innovation and research, Celltrion has emerged as a global leader in developing and producing biosimilar and innovative biopharmaceuticals. The company has a diverse portfolio of products, including treatments for autoimmune diseases, cancer, and infectious diseases. Celltrion's commitment towards delivering high-quality therapeutics at an affordable cost has garnered international recognition. By leveraging its expertise in biotechnology, Celltrion continues to strive towards improving healthcare standards and ensuring patient well-being. With a successful track record and a dedication to advancing medical advancements, Celltrion Inc has established itself as a prominent player in the pharmaceutical industry.

Celltrion Inc has achieved several significant milestones. One notable achievement is the approval and successful launch of their biosimilar drugs, such as Inflectra and Remsima, which have had a positive impact on the healthcare industry. Additionally, Celltrion Inc has made advancements in research and development, particularly in the field of monoclonal antibodies for diseases like cancer and autoimmune disorders. The company has also expanded its global reach by securing strategic partnerships and collaborations with other pharmaceutical companies. These milestones demonstrate Celltrion Inc's commitment to innovation and its ability to produce high-quality biopharmaceutical products.

Celltrion Inc is primarily present in South Korea.

Celltrion Inc represents values of innovation, growth, and commitment. The company's corporate philosophy revolves around advancing healthcare through the development of biopharmaceuticals and biosimilars. With a focus on research and development, Celltrion Inc aims to provide effective and affordable treatment options for patients worldwide. By harnessing cutting-edge technology and fostering collaboration, the company strives to make significant contributions to the field of biotechnology. Celltrion Inc's commitment to delivering high-quality products and improving global healthcare standards makes it a prominent player in the pharmaceutical industry.

Analysts currently set an average price target of 249,012.13 KRW for the Celltrion stock (median: 255,000.00 KRW), implying +30.4 % versus the latest price. The consensus is based on 28 analyst ratings.

Celltrion Analyst Price Targets 2026

28 analysts currently rate the Celltrion stock: 25 recommend buying, 2 holding and 1 selling. For 2026, analysts expect Celltrion to generate revenue of 5.36 T KRW and earnings per share of 6,145.89 KRW.

Celltrion Analyst Price Targets 2026

Converted at the current exchange rate, the Celltrion share trades at 111.23 EUR (183,000.00 KRW).

Celltrion Inc. is a Korean biotechnology company that specializes in the research, development, and manufacturing of biological drugs. The company was founded in 2002 and is headquartered in Incheon, South Korea. Celltrion Inc. is involved in various business areas, including the development of biosimilars, distribution of biologics, and development of antibiotics.

The expected revenue of Celltrion is 5.36 T KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Celltrion is 1.37 T KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Celltrion is currently 29.78. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Celltrion stock.

The price-to-sales ratio (P/S) of Celltrion is currently 7.62. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Celltrion stock.

The Eulerpool Quality Score for Celltrion is 7/10.

The ISIN of Celltrion is KR7068270008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Celltrion is A0RM6K. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Celltrion is 068270.KS. The ticker symbol is used to trade Celltrion shares on the stock exchange.

Over the past 12 months, Celltrion paid a dividend of 714.29 KRW . This corresponds to a dividend yield of about 0.39 %. For the coming 12 months, Celltrion is expected to pay a dividend of 1,028.57 KRW.

The current dividend yield of Celltrion is 0.39 %.

Celltrion pays a dividend, distributed in the months of , , , .

Celltrion paid dividends every year for the past 5 years.

For the upcoming 12 months, dividends amounting to 1,028.57 KRW are expected. This corresponds to a dividend yield of 0.56 %.

Celltrion is assigned to the 'Health' sector.

To receive the latest dividend of Celltrion from amounting to 750 KRW, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Celltrion distributed 654.11 KRW as dividends.

The dividends of Celltrion are distributed in KRW.

All fundamentals and in-depth analysis of Celltrion

Our stock analysis for Celltrion stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celltrion. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Celltrion Stock
Celltrion Revenue→
Celltrion Stock
Celltrion Net Income→
Celltrion Stock
Celltrion P/E→
Celltrion Stock
Celltrion P/S→
Celltrion Stock
Celltrion EBIT→
Celltrion Stock
Celltrion Dividend→
Celltrion Stock
Celltrion Directors Dealings→
Celltrion Stock
Celltrion Stocks→
Celltrion Stock
Celltrion Market capitalization→
Celltrion Stock
Celltrion Debt→
Celltrion Stock
Celltrion Liabilities→
Celltrion Stock
Celltrion Equity→
Celltrion Stock
Celltrion AAQS→
Celltrion Stock
Celltrion Employees→
Celltrion Stock
Celltrion ROE→
Celltrion Stock
Celltrion ROA→
Celltrion Stock
Celltrion ROCE→
Celltrion Stock
Celltrion News→
Celltrion Stock
Celltrion Analyst Price Targets→

Health Stocks

Celltrion PharmCellSource CoCellumed CoCellSeedCelon PharmaCellid CoCelularityCellectisCelyad OncologyCellectar BiosciencesCenraCelldex TherapeuticsAll Stocks A–Z →